Mitoxantrone
- Generic Name
- Mitoxantrone
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28N4O6
- CAS Number
- 65271-80-9
- Unique Ingredient Identifier
- BZ114NVM5P
- Background
An anthracenedione-derived antineoplastic agent.
- Indication
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma
- Associated Therapies
- Autologous hematopoietic stem cell transplant
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT05955261
- Locations
- 🇺🇸
Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States
🇺🇸Valley Children's Hospital, Madera, California, United States
🇺🇸Rady Children's Hospital-San Diego, San Diego, California, United States
Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2024-03-15
- Target Recruit Count
- 90
- Registration Number
- NCT05941585
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 104
- Registration Number
- NCT05875428
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Shandong First Medical University, Jinan, Shandong, China
Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Second Affiliated Hospital of Soochow University
- Target Recruit Count
- 20
- Registration Number
- NCT05857982
- Locations
- 🇨🇳
Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
- Conditions
- Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Tanja Andrea Gruber
- Target Recruit Count
- 90
- Registration Number
- NCT05848687
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2023-03-27
- Target Recruit Count
- 60
- Registration Number
- NCT05784987
R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Drug: Vincristine/Vindesine
- First Posted Date
- 2023-03-21
- Last Posted Date
- 2023-03-21
- Target Recruit Count
- 30
- Registration Number
- NCT05777369
M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2023-02-22
- Lead Sponsor
- The First Affiliated Hospital of Soochow University
- Target Recruit Count
- 60
- Registration Number
- NCT05739630
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment
- Conditions
- Recurrent Metastatic Nasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-02-08
- Target Recruit Count
- 500
- Registration Number
- NCT05717764
Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors
- Conditions
- Pediatric Solid Tumor
- Interventions
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 68
- Registration Number
- NCT05620862
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.